Collette Menadue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Collette Menadue has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Amanda Piper
Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital, Camperdown (NSW), Australia
2 shared publications- Amanda Jane Piper
Department of Respiratory and Sleep Medicine Royal Prince Alfred Hospital Camperdown New South Wales Australia
1 shared publication - Benjamin Nguyen
St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia
1 shared publication - Brendon J. Yee
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
1 shared publication Brendon Yee
Department of Respiratory & Sleep Medicine, Royal Prince Alfred Hospital; Central Clinical Medical School, The University of Sydney; Sleep Research Group, The Woolcock Institute of Medical Research, Camperdown (NSW), Australia
1 shared publication- Edmund M. T. Lau
Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia
1 shared publication
Latest Publications
- Open Access
- 23 October 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002496
Long-term mortality in patients with chronic obstructive pulmonary disease requiring acute non-invasive ventilation with and without obstructive sleep apnoea
Introduction: Chronic obstructive pulmonary disease (COPD)/obstructive sleep apnoea (OSA) overlap syndrome (OVS) is associated with higher mortality compared with COPD alone in stable outpatients. However, the prognosis of patients hospitalised with acute hypercapnic respiratory failure (ARF) is unclear. Methods: In this retrospective cohort study, 124 patients with COPD and 44 patients with OVS were treated with positive airway pressure (PAP) for ARF and followed up for a median of 20.6 months (IQR 3.80–53.4). Patients treated in the emergency or intensive care units and did not continue PAP on the wards were excluded. We compared patient characteristics and overall survival. Results: Mean (SD) age of participants was 71 (9.7) years and 51% were males. Patients with OVS had a higher prevalence of hypertension (75% vs 50.0%, p=0.004) and type 2 diabetes mellitus (45.5% vs 19.4%, p<0.001). There was no difference in arterial pH or carbon dioxide levels at presentation. On univariate analysis, mortality was lower in OVS compared with patients with COPD alone (HR 0.57, 95% CI 0.37 to 0.87). Median survival was 51.0 (95% CI 38.1 to 93.7) months in OVS and 27.7 (95% CI 16.9 to 35.1) months in COPD alone. Median survival in OVS prescribed home PAP therapy was significantly higher (59.0 months) compared with OVS not discharged on therapy (36.1 months), and to patients with COPD, irrespective of home therapy prescription (p=0.022). After adjusting for multiple known confounders, patients with OVS still appeared to have lower mortality; however, this was no longer statistically significant (HR 0.75, 95% CI 0.45 to 1.24). Discussion: We found that patients with COPD and ARF requiring non-invasive ventilation may have higher mortality rates compared with patients with OVS. Patients with OVS treated with home PAP had lower mortality compared with patients not prescribed PAP on discharge. These findings suggest that patients with COPD who present with ARF may benefit from early diagnosis of OSA and initiation of long-term PAP therapy.
- 23 October 2024
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 11 (1) , e002496
Open AccessLong-term mortality in patients with chronic obstructive pulmonary disease requiring acute non-invasive ventilation with and without obstructive sleep apnoea
Introduction: Chronic obstructive pulmonary disease (COPD)/obstructive sleep apnoea (OSA) overlap syndrome (OVS) is associated with higher mortality compared with COPD alone in stable outpatients. However, the prognosis of patients hospitalised with acute hypercapnic respiratory failure (ARF) is unclear. Methods: In this retrospective cohort study, 124 patients with COPD and 44 patients with OVS were treated with positive airway pressure (PAP) for ARF and followed up for a median of 20.6 months (IQR 3.80–53.4). Patients treated in the emergency or intensive care units and did not continue PAP on the wards were excluded. We compared patient characteristics and overall survival. Results: Mean (SD) age of participants was 71 (9.7) years and 51% were males. Patients with OVS had a higher prevalence of hypertension (75% vs 50.0%, p=0.004) and type 2 diabetes mellitus (45.5% vs 19.4%, p<0.001). There was no difference in arterial pH or carbon dioxide levels at presentation. On univariate analysis, mortality was lower in OVS compared with patients with COPD alone (HR 0.57, 95% CI 0.37 to 0.87). Median survival was 51.0 (95% CI 38.1 to 93.7) months in OVS and 27.7 (95% CI 16.9 to 35.1) months in COPD alone. Median survival in OVS prescribed home PAP therapy was significantly higher (59.0 months) compared with OVS not discharged on therapy (36.1 months), and to patients with COPD, irrespective of home therapy prescription (p=0.022). After adjusting for multiple known confounders, patients with OVS still appeared to have lower mortality; however, this was no longer statistically significant (HR 0.75, 95% CI 0.45 to 1.24). Discussion: We found that patients with COPD and ARF requiring non-invasive ventilation may have higher mortality rates compared with patients with OVS. Patients with OVS treated with home PAP had lower mortality compared with patients not prescribed PAP on discharge. These findings suggest that patients with COPD who present with ARF may benefit from early diagnosis of OSA and initiation of long-term PAP therapy.
- 15 February 2024
- Published by European Respiratory Society (ERS)
- Vol. 10 (suppl 13)
Effect of heated humidification circuit type on pressure and tidal volume delivery during non-invasive ventilation: A benchtop study
Background: Humidification circuit type and performance of a circuit calibration may affect pressure and tidal volume (VT) delivery during NIV. Aims: To determine the effect of three different humidification circuits on pressure and VT delivery in the setting of normal lungs, increased airway resistance (RAW) and reduced lung compliance (CL). Method: Using a life-support ventilator (Philips Trilogy Evo©), three circuits (standard tubing (ResMed), RT-202 (Fisher & Paykel), 950A61 (Fisher & Paykel)) were connected to a test lung and delivered inspiratory positive airway pressure (IPAP) and VT were measured. Each circuit was tested under 9 randomly ordered experimental conditions that combined: respiratory mechanics (normal, increased RAW, decreased CL) and IPAP (10, 15, 20cmH2O). Expiratory posiitve airway pressure was set at 5cmH2O. The effect of circuit calibration was also tested for RT-202 and 950A61 circuits. Results: Pooled data from all IPAP and lung conditions showed a calibrated RT202 circuit reduced delivered IPAP (-0.3cmH2O [95%CI -0.29 to -0.31]) and VT (-39ml [-38, -40]) compared with a standard circuit. In contrast, small increases in delivered IPAP (0.2cmH2O [0.19, 0.21] and VT (7ml [6.1, 7.6] were seen with the 950A61 circuit compared to standard tubing. Delivered IPAP was closer to set IPAP for the 950A61 circuit. The greatest drop in VT was 87mL (-89 to -86) with the RT202 and increase in IPAP was 0.91cmH2O (0.88 to 0.93) with the 950A61 at set IPAP 20cmH2O. Circuit calibration increased VT and measured IPAP for both RT202 and 950A61 circuits. Conclusion: Changing humidifier circuit type can significantly impact pressure and VT delivery.
- 15 February 2024
- Published by European Respiratory Society (ERS)
- Vol. 10 (suppl 13)
Effect of heated humidification circuit type on pressure and tidal volume delivery during non-invasive ventilation: A benchtop study
Background: Humidification circuit type and performance of a circuit calibration may affect pressure and tidal volume (VT) delivery during NIV. Aims: To determine the effect of three different humidification circuits on pressure and VT delivery in the setting of normal lungs, increased airway resistance (RAW) and reduced lung compliance (CL). Method: Using a life-support ventilator (Philips Trilogy Evo©), three circuits (standard tubing (ResMed), RT-202 (Fisher & Paykel), 950A61 (Fisher & Paykel)) were connected to a test lung and delivered inspiratory positive airway pressure (IPAP) and VT were measured. Each circuit was tested under 9 randomly ordered experimental conditions that combined: respiratory mechanics (normal, increased RAW, decreased CL) and IPAP (10, 15, 20cmH2O). Expiratory posiitve airway pressure was set at 5cmH2O. The effect of circuit calibration was also tested for RT-202 and 950A61 circuits. Results: Pooled data from all IPAP and lung conditions showed a calibrated RT202 circuit reduced delivered IPAP (-0.3cmH2O [95%CI -0.29 to -0.31]) and VT (-39ml [-38, -40]) compared with a standard circuit. In contrast, small increases in delivered IPAP (0.2cmH2O [0.19, 0.21] and VT (7ml [6.1, 7.6] were seen with the 950A61 circuit compared to standard tubing. Delivered IPAP was closer to set IPAP for the 950A61 circuit. The greatest drop in VT was 87mL (-89 to -86) with the RT202 and increase in IPAP was 0.91cmH2O (0.88 to 0.93) with the 950A61 at set IPAP 20cmH2O. Circuit calibration increased VT and measured IPAP for both RT202 and 950A61 circuits. Conclusion: Changing humidifier circuit type can significantly impact pressure and VT delivery.
- 15 February 2024
- Published by European Respiratory Society (ERS)
- Vol. 10 (suppl 13)
Does normoxia exclude hypercapnia in people with neuromuscular disease? A retrospective analysis of arterial blood gases
Background: Pulse oximetry is widely used in the assessment of chronic hypercapnic respiratory failure (CHRF) in people with neuromuscular disease (NMD). Guidelines suggest an arterial blood gas (ABG) is indicated if oxygen saturations (SpO2) ≤ 94% in the absence of lung disease. However, hypercapnia with normoxia (SpO2 ≥ 95%) has been observed on ABGs of patients with NMD. Aims: To determine the prevalence of hypercapnia with normoxia in people with CHRF. It was hypothesised that hypercapnia with normoxia would occur in a small proportion of NMD patients. Methods: A single-centre retrospective audit of room-air ABGs in stable CHRF patients from 1990–2020 was performed. Patients with parenchymal lung disease were excluded. Patients were grouped into three main categories: non-NMD, other-NMD and motor neurone disease (MND). Results: Three-hundred-and-six ABGs with hypercapnia from 185 patients with extrinsic restrictive lung disease were analysed. No patients with non-NMD, 65% of other-NMD and 36% of MND patients demonstrated hypercapnia with normoxia (χ2 83·61; p<0·001). The potential mechanism is proposed to be a difference in calculated respiratory quotient (RQ). Assuming the A-a gradient is normal, the calculated RQ was significantly higher in MND patients and other-NMD patients compared with non-NMD patients (estimated-marginal-mean 0·99 [95%CI 0·93–1·03]; 0·88 [95%CI 0·77–0·97]; 0·74 [95%CI 0·64—0·84] respectively; p<0·001) by mixed-model analysis. Conclusion: Hypercapnia is not excluded with normal oximetry in people with NMD and may be due to an elevated RQ. This has implications in the diagnosis and monitoring of CHRF in people with NMD with oximetry alone.
- 15 February 2024
- Published by European Respiratory Society (ERS)
- Vol. 10 (suppl 13)
Does normoxia exclude hypercapnia in people with neuromuscular disease? A retrospective analysis of arterial blood gases
Background: Pulse oximetry is widely used in the assessment of chronic hypercapnic respiratory failure (CHRF) in people with neuromuscular disease (NMD). Guidelines suggest an arterial blood gas (ABG) is indicated if oxygen saturations (SpO2) ≤ 94% in the absence of lung disease. However, hypercapnia with normoxia (SpO2 ≥ 95%) has been observed on ABGs of patients with NMD. Aims: To determine the prevalence of hypercapnia with normoxia in people with CHRF. It was hypothesised that hypercapnia with normoxia would occur in a small proportion of NMD patients. Methods: A single-centre retrospective audit of room-air ABGs in stable CHRF patients from 1990–2020 was performed. Patients with parenchymal lung disease were excluded. Patients were grouped into three main categories: non-NMD, other-NMD and motor neurone disease (MND). Results: Three-hundred-and-six ABGs with hypercapnia from 185 patients with extrinsic restrictive lung disease were analysed. No patients with non-NMD, 65% of other-NMD and 36% of MND patients demonstrated hypercapnia with normoxia (χ2 83·61; p<0·001). The potential mechanism is proposed to be a difference in calculated respiratory quotient (RQ). Assuming the A-a gradient is normal, the calculated RQ was significantly higher in MND patients and other-NMD patients compared with non-NMD patients (estimated-marginal-mean 0·99 [95%CI 0·93–1·03]; 0·88 [95%CI 0·77–0·97]; 0·74 [95%CI 0·64—0·84] respectively; p<0·001) by mixed-model analysis. Conclusion: Hypercapnia is not excluded with normal oximetry in people with NMD and may be due to an elevated RQ. This has implications in the diagnosis and monitoring of CHRF in people with NMD with oximetry alone.
- 29 August 2023
- Published by Springer Nature
- p. 709-727
Noninvasive Ventilation During Rehabilitation